Ph II Study of Oral Selective AXL Inhibitor Bemcentinib (BGB324) in Combination with Pembrolizumab in Patients with Advanced NSCLC

Simple item page
dc.contributor.authorArce-Lara, C.
dc.contributor.authorArriola, E.
dc.contributor.authorBrunsvig, P.
dc.contributor.authorCarcereny, E.
dc.contributor.authorDomine, M.
dc.contributor.authorDragnev, K.
dc.contributor.authorFelip, E.
dc.contributor.authorGarcia Campelo, R.
dc.contributor.authorKrebs, M.
dc.contributor.authorPaz-Ares, L.
dc.contributor.authorPonce Aix, S.
dc.contributor.authorSpicer, J.
dc.contributor.authorTrigo, J. M.
dc.contributor.authorVinolas Segarra, N.
dc.contributor.authorHolt, R.
dc.contributor.authorMicklem, D.
dc.contributor.authorBrown, A.
dc.contributor.authorChisamore, M.
dc.contributor.authorLorens, J.
dc.contributor.authoraffiliation[Arce-Lara, C.] Med Coll Wisconsin, Med, Milwaukee, WI 53226 USA
dc.contributor.authoraffiliation[Arriola, E.] Hosp Del Mar, Med Oncol Dept, Barcelona, Spain
dc.contributor.authoraffiliation[Brunsvig, P.] Radiumhosp, Oslo, Norway
dc.contributor.authoraffiliation[Carcereny, E.] Hosp Badalona Germans Trias & Pujol, Catalan Inst Oncol, Med Oncol, Badalona, Spain
dc.contributor.authoraffiliation[Domine, M.] Fdn Jimenez Diaz, Madrid, Spain
dc.contributor.authoraffiliation[Dragnev, K.] Dartmouth Hitchcock Med Ctr, Lebanon, NH 03766 USA
dc.contributor.authoraffiliation[Felip, E.] Vall DHebron Univ Hosp, Barcelona, Spain
dc.contributor.authoraffiliation[Garcia Campelo, R.] Hosp Teresa Herrera, La Coruna, Spain
dc.contributor.authoraffiliation[Krebs, M.] Univ Manchester, Manchester, Lancs, England
dc.contributor.authoraffiliation[Krebs, M.] Christie NHS Fdn Trust, Manchester, Lancs, England
dc.contributor.authoraffiliation[Paz-Ares, L.] Hosp Univ 12 Octubre, Madrid, Spain
dc.contributor.authoraffiliation[Ponce Aix, S.] Hosp Univ 12 Octubre, Madrid, Spain
dc.contributor.authoraffiliation[Spicer, J.] Kings Coll London, Guys Hosp, London, England
dc.contributor.authoraffiliation[Trigo, J. M.] Hosp Univ Virgen La Victoria, Oncol Med, Malaga, Spain
dc.contributor.authoraffiliation[Vinolas Segarra, N.] Hosp Clin Barcelona, Barcelona, Spain
dc.contributor.authoraffiliation[Holt, R.] Bergenbio Asa, Bergen, Norway
dc.contributor.authoraffiliation[Micklem, D.] Bergenbio Asa, Bergen, Norway
dc.contributor.authoraffiliation[Brown, A.] Bergenbio Asa, Bergen, Norway
dc.contributor.authoraffiliation[Chisamore, M.] Merck & Co Inc, Kenilworth, NJ USA
dc.contributor.authoraffiliation[Lorens, J.] Univ Bergen, Bergen, Norway
dc.date.accessioned2025-01-07T15:05:00Z
dc.date.available2025-01-07T15:05:00Z
dc.date.issued2018-10-01
dc.identifier.doi10.1016/j.jtho.2018.08.1251
dc.identifier.essn1556-1380
dc.identifier.issn1556-0864
dc.identifier.unpaywallURLhttp://www.jto.org/article/S1556086418322093/pdf
dc.identifier.urihttps://hdl.handle.net/10668/26868
dc.identifier.wosID454014502402
dc.issue.number10
dc.issue.numberS
dc.journal.titleJournal of thoracic oncology
dc.journal.titleabbreviationJ. thorac. oncol.
dc.language.isoen
dc.organizationSAS - Hospital Universitario Virgen de la Victoria
dc.page.numberS741-S741
dc.publisherElsevier science inc
dc.rights.accessRightsopen access
dc.subjectAxl
dc.subjectpembrolizumab
dc.subjectcombination
dc.titlePh II Study of Oral Selective AXL Inhibitor Bemcentinib (BGB324) in Combination with Pembrolizumab in Patients with Advanced NSCLC
dc.typeconference output
dc.type.hasVersionVoR
dc.volume.number13
dc.wostypeMeeting Abstract

Files

Collections

SAS - Hospital Universitario Virgen de la Victoria

© 2023 – Repositorio Institucional de Salud de Andalucía - Fundación Pública Andaluza Progreso y Salud - Consejería de Salud y Consumo de la Junta de Andalucía